Reply to: "Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Definitively Does Not Deserve Its Bad Reputation".
作者信息
Horvath Philipp, Yurttas Can
机构信息
Department of General, Visceral and Transplant Surgery, Comprehensive Cancer Center, University of Tübingen, Tübingen, Germany.
National Center for Pleura and Peritoneum, University of Tübingen, 72076, Tübingen, Germany.
出版信息
Ann Surg Oncol. 2021 Sep;28(9):5450-5451. doi: 10.1245/s10434-021-09743-z. Epub 2021 Feb 26.
Abstract
摘要
相似文献
1
Reply to: "Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Definitively Does Not Deserve Its Bad Reputation".
Ann Surg Oncol. 2021 Sep;28(9):5450-5451. doi: 10.1245/s10434-021-09743-z. Epub 2021 Feb 26.
2
Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Definitively Does not Deserve Its Bad Reputation.
Ann Surg Oncol. 2021 Sep;28(9):5448-5449. doi: 10.1245/s10434-021-09741-1. Epub 2021 Feb 20.
3
Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience.
J Surg Oncol. 2021 Mar;123(4):1030-1044. doi: 10.1002/jso.26371. Epub 2021 Feb 1.
4
Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy, Part II: Implementation.
AORN J. 2019 Dec;110(6):606-625. doi: 10.1002/aorn.12865.
5
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Technical considerations and the learning curve.
J Surg Oncol. 2020 Jul;122(1):85-95. doi: 10.1002/jso.25939. Epub 2020 May 20.
6
Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
J Surg Oncol. 2015 Jun;111(7):840-7. doi: 10.1002/jso.23889. Epub 2015 Apr 10.
7
[Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Mar 25;24(3):230-239. doi: 10.3760/cma.j.cn.441530-20201110-00603.
8
Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy, Part I: Introduction and Indications.
AORN J. 2019 Nov;110(5):479-499. doi: 10.1002/aorn.12842.
9
Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
Eur J Surg Oncol. 2021 Jun;47(6):1411-1419. doi: 10.1016/j.ejso.2020.11.139. Epub 2020 Dec 1.
10
Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?
Int J Hyperthermia. 2016 May;32(3):281-8. doi: 10.3109/02656736.2015.1135485. Epub 2016 Feb 10.
本文引用的文献
1
In-Hospital Mortality and Complication Rates According to Health Insurance Data in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies in Germany.
Ann Surg Oncol. 2021 Jul;28(7):3823-3830. doi: 10.1245/s10434-020-09301-z. Epub 2020 Nov 9.
2
Centralization and Oncologic Training Reduce Postoperative Morbidity and Failure-to-rescue Rates After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: Study on a 10-year National French Practice.
Ann Surg. 2020 Nov;272(5):847-854. doi: 10.1097/SLA.0000000000004326.
Zotero 插件